Aim of the study: The aim of this retrospective study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) expression changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

Material and methods: Fifty patients with locally advanced rectal cancer were evaluated. All the patients were administered the total dose of 44 Gy. Capecitabine has been concomitantly administered in the dose 825 mg/m² in two daily oral administrations. Surgery was indicated 4–8 weeks from the chemoradiotherapy completion. Epidermal growth factor receptor expression in the pretreatment biopsies and in the resected specimens was assessed with immunohistochemistry.

Results: All of 50 patients received radiotherapy without interruption up to the total planned dose. In 30 patients sphincter-saving surgery was performed, 20 patients underwent amputation of the rectum. Downstaging was described in 30 patients. Four patients have had complete pathologic remission. Twenty-six patients have had partial remission, the disease was stable in 15 patients. Progression was reported in 5 patients. The median disease-free survival was 64.9 months, median overall survival was 76.4 months. Increased EGFR expression was found in 12 patients (26.1%). A statistically significantly shorter overall survival ($p < 0.0001$) and disease-free survival ($p < 0.0001$) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR during neoadjuvant chemoradiotherapy was observed.

Conclusions: The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma associated with significant shorter overall survival and disease free survival.

Key words: rectal adenocarcinoma, neoadjuvant treatment, radiotherapy, chemotherapy, epidermal growth factor receptor.


The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma

Igor Richter¹, Josef Dvořák², Marek Urbanec³, Antonín Bluml⁴, Eva Čermáková⁵, Jiří Bartoš⁶, Jiří Petera²

¹Department of Oncology, Regional Hospital Liberec, Liberec, Czech Republic
²Department of Oncology and Radiotherapy, Charles University, Medical School and Teaching Hospital, Hradec Královo, Czech Republic
³Department of Pathology, Ceska Lipa Hospital, Ceska Lipa, Czech Republic
⁴Department of Medical Biophysics, Charles University, Medical School and Teaching Hospital, Hradec Královo, Czech Republic
⁵Department of Medical Biophysics, Charles University, Medical School and Teaching Hospital, Hradec Královo, Czech Republic
⁶Department of Oncology, Regional Hospital Liberec, Liberec, Czech Republic

Introduction

Malignant tumours of the colon and rectum are the most common cancers in developed countries. The incidence of rectal adenocarcinoma represents approximately 30% of this number. A neoadjuvant chemoradiotherapy followed by total mesorectal excision is the basic procedure of the treatment for patients with locally advanced rectal cancer. Neoadjuvant chemoradiotherapy has shown a lower incidence of local recurrence and better toxicity profile compared to adjuvant therapy, but no survival benefit was shown [1]. Potentiation with 5-fluorouracil or capecitabine has shown a higher percentage of pathological complete remission and a lower percentage of local recurrence compared to the treatment with radiotherapy alone [2–5]. The development of molecular biology enables us to look for other predictive factors of overall outcomes. One of them is receptor for epidermal growth factor (EGFR). The overexpression of EGFR is observed in 50–80% of rectal carcinomas and is associated with a worse prognosis [6–8]. Radiobiological EGFR studies confirm the critical role of cytoprotective and pro-proliferative responses of tumour cells after irradiation. The increase in EGFR expression after radiotherapy is related to accelerated repopulation of cancer cells [9, 10]. Increased tumour repopulation during radiotherapy leads to the recovery of clonogenic tumour cells, thereby causing counter productivity to radiation therapy alone [11–13]. Based on the above information, the inhibition of EGFR function during cancer treatment is one of the most investigated processes. Monoclonal antibodies against EGFR have reached the greatest expansion. Cetuximab and panitumumab are used in the treatment of metastatic colorectal cancer [14–18]. Neoadjuvant treatment of rectal adenocarcinoma has been the topic of several clinical papers evaluating the benefits of monoclonal antibodies against EGFR combined with chemoradiotherapy. Most dates are for cetuximab [19–21]. Conversely, the percentage of pathological complete response (pCR) was low (5–8%) compared to the percentage of pCR in separate chemoradiotherapy. According to a meta-analysis of phase II and III in clinical trials...
The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma

In 3157 patients, pCR was described in 13.5% of treated patients with neoadjuvant chemoradiotherapy [22]. Panitumumab was evaluated in a phase II clinical study in the neoadjuvant treatment of rectal adenocarcinoma. A total of 60 patients were evaluated. The percentage of complete pathologic remissions was 21.1% [23]. Therefore more options of how to better individualise the treatment of patients with EGFR inhibitors are being looked for. The aim of this retrospective study was to determine the prognostic impact of EGFR expression changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer, by comparison of EGFR expression in pretreatment endoscopic biopsies and resection specimens after neoadjuvant chemoradiotherapy.

Material and methods

Between January 2005 and December 2009 a total of 59 patients were treated with preoperative radiation for rectal adenocarcinoma potentiated with capecitabine in the Department of Oncology, Liberec Hospital. Fifty patients, 34 men and 16 women, were evaluated. Nine patients were not evaluated because of incomplete clinical and pathological data. The mean age was 61.4 years (range 40–78 years). Microscopically, tubular adenocarcinoma was identified in all 50 patients. Mucinous component was described in three patients. Histologically, the tumour was a well-differentiated adenocarcinoma in 3 patients, moderately differentiated in 38 patients, and poorly differentiated in 9 patients. As far as the anatomical site is concerned, 24 patients had a distal tumour margin localised as far as 5 cm from the internal sphincter, and the same number of patients had between 5.1 and 10 cm. The case of the distal edge of the tumour penetrating more than 10 cm was described in two patients. Before the neoadjuvant chemoradiotherapy was started, 28 patients were in the second clinical stage and 22 patients in the third clinical stage, according to TNM classification.

Treatment

The source of radiation was a linear accelerator Elekta Precise or Elekta Synergy (Elekta, Sweden). We used ionising photon radiation with an energy of 15 MeV. Patients were irradiated using the 3D conformal radiotherapy technique, or IMRT, using segmented fields. All the patients were administered a total dose of 44 Gy (fractionation of 2 Gy) in 22 fractions to the tumour area, mesorectum, and pelvic regional lymph nodes [24]. Capecitabine was concomitantly administered with a dosage of 825 mg/m² in two daily oral administrations for the whole duration of radiotherapy, including weekends. Surgery was indicated at intervals of 4–8 weeks from the completion of chemoradiotherapy.

Immunohistochemical determination of epidermal growth factor receptor

The evaluation was semi-quantitative, and the colour intensity of at least 1% of tumour cells was assessed as follows: 0 = none, 1+ = mild, 2+ = moderate, 3+ = severe (Figs. 1–3). A commercial kit (EGFR PharmDxTM, Dako, Denmark) was used. Slides were evaluated by an experienced pathologist who was not familiar with the treatment results of the patients. Endobioptic findings before treatment as well as resection specimens after neoadjuvant chemoradiotherapy and surgical treatment were analysed in our patient group.
47 patients, and microscopically positive margin was de-
scribed by a pathologist in 3 patients. There was no sur-
gically macroscopic residue left in any patient. According
to the pathological TNM classification, 14 patients were at
the first clinical stage, 24 patients in the second clinical
stage, and 8 patients in the third clinical stage after the
operation. Four patients achieved complete pathological
remission. Complete pathological response was defined as
the absence of tumour tissue in the specimen. No patient
had the generalisation of the disease described intraop-
eratively. Downstaging was described in 30 patients. Four
patients had complete pathologic remission. Twenty-six
patients had partial remission. The disease was stable
in 15 patients. Progression was reported in 5 patients. At
the time of assessment (31 December 2013) median fol-
low-up was 51.3 months. A recurrence occurred in 25 pa-
tients, and 25 patients had no signs of recurrence. Local
recurrence was found in 8 patients, and generalisation of
disease was reported in 17 patients. The most common
sites of metastases were the liver (eight patients) and
lungs (seven patients). One patient suffered from brain
metastases, and metastatic involvement of retroperitone-
al lymph nodes was found in one patient. The median DFS
was 64.9 months (95% CI: 26.1 to 67.8 months). The 3-year
DFS was 56%. A total of 21 patients died, and 29 patients
remained alive. The median OS was 76.4 months (95% CI:
57.3 to 76.9 months). The 3-year OS was 92%. Epidermal
growth factor receptor expression was examined both by
endobiopsy and in resection specimens after neoadjuvant
chemoradiotherapy. The impact of EGFR expression on treat-
mant outcomes (OS, DFS) was assessed by the log-rank test. All
the statistical tests were performed at the significance lev-
el $\alpha = 0.05$.

### Results

All of the 50 patients received radiotherapy without in-
terruption up to the total planned dose. No patient died
during the treatment. Concomitant chemotherapy was
discontinued prematurely in four patients because of haem-
atological and gastrointestinal toxicity. No patient was
hospitalised because of acute treatment toxicity. Non-hae-
matological toxicity evaluation did not achieve grade III or
IV. Anaemia grade III was found in one patient. The median
time between chemoradiotherapy completion and surgery
was 44 days (6.3 weeks). In 30 patients sphincter-saving
surgery was performed, and 20 patients underwent am-
putation of the rectum. R0 resection was performed in
47 patients, and microscopically positive margin was de-

### Table 1. Epidermal growth factor receptor (EGFR) expression score in
biopsies and resected specimens

<table>
<thead>
<tr>
<th>EGFR expression score</th>
<th>EGFR expression in pretreatment biopsies N (%)</th>
<th>EGFR expression in resected specimen N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>22 (44)</td>
<td>23 (46)</td>
</tr>
<tr>
<td>1+</td>
<td>18 (36)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>2+</td>
<td>5 (10)</td>
<td>11 (22)</td>
</tr>
<tr>
<td>3+</td>
<td>5 (10)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>Not applicable</td>
<td>0 (0)</td>
<td>4 (8)</td>
</tr>
</tbody>
</table>

### Statistical analysis

The statistical evaluation was performed using the
Number Cruncher Statistical Systems 9 NCSS (Kaysville,
Utah, USA) program. Overall survival (OS) = time from
the first histological verification until death or the date of
the last check for survivors. Disease-free survival (DFS) = time
from surgery to distant or local recurrence or the last con-
trol of a patient without recurrence. The overall survival
and disease-free survival was assessed using Kaplan-Mei-
er analysis. The impact of EGFR expression on treatment
outcomes (OS, DFS) was assessed by the log-rank test. All
the statistical tests were performed at the significance lev-
el $\alpha = 0.05$.

### Discussion

Our retrospective study confirmed its target and proved
that patients with increased expression of EGFR during
neoadjuvant chemoradiotherapy demonstrate significant-
ly shorter OS and DFS. We demonstrated increased expres-
sion of EGFR in 12 patients, i.e. 26.1% of all evaluated pa-
tients. In 2012, a retrospective study examining the effects
The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma

Nyati et al. discussed in their paper whether the cause could be seen in the suboptimal sequence of administered treatment that might lead to an antagonistic rather than a potentiating effect [37]. It was found that EGFR inhibitors cause the redistribution of the cell cycle by G1 phase blockade [36]. Administration of EGFR inhibitors before the cytostatic scan arrested the cell cycle in the G1 phase, which can affect the attenuation of the effects of subsequently administered cytostatics, with an impact on other phases of the cell cycle. It is the cytostatics used in the treatment of colorectal cancer (5-fluorouracil, oxaliplatin, irinotecan) that have the most highlighted effect on the cell cycle in the S/G2/M phase of the cell cycle [19]. The administration of EGFR inhibitors leads to a reduction in tumour proliferation. Conversely, radiotherapy has a lesser effect on the less proliferating tumour cells. This is another cause of lower pathological complete remission after the concomitant treatment with EGFR inhibitors and radiotherapy [38]. The variation in the prognostic significance of EGFR in clinical studies may also be associated with the method of determining the EGFR expression [26, 27, 39, 40]. It can be obtained from a combination of various influences such as the sampling method, preparation of tissue samples, the method of receptor activity evaluation, and others. On the basis of the results of the current retrospective study it would be appropriate to identify a group of patients with increased EGFR expression during neoadjuvant chemoradiotherapy. This group of patients would gain benefit from additional therapy by EGFR inhibitors after surgery. In the future, prospective studies could take advantage not only of immunohistochemistry ex vivo, but also of immunohistochemistry in vivo using PET EGFR, which could evaluate the dynamics of EGFR expression not only before and after chemoradiotherapy, but also during chemoradiotherapy with early antiEGFR therapy [41].

In conclusion, the increase of EGFR expression during neoadjuvant chemoradiotherapy for locally advanced rectal cancer is associated with significantly shorter overall survival and disease-free survival.

The authors declare no conflict of interest.
References

tive chemoradiotherapy for rectal cancer: results of the German
CAO/ARO/AIO-94 randomised phase III trial after a median fol-

of chemotherapy with preoperative radiotherapy for rectal cancer:

with or without concurrent fluorouracil and leucovorin in T3-4

capcitabine versus fluorouracil for locally advanced rectal cancer:
a randomised, multicentre, non-inferiority, phase 3 trial. Lanc-

5. De Caluwé V, Van Nieuwenhove V, Ceelen WP. Preoperative
chemoradiation versus radiation alone for stage II and III re-
sectable rectal cancer. Cochrane Database Syst Rev 2013; 2:
CD006041.

6. Steele RJ, Kelly P, Ellul B, Ermin O. Epidermal growth factor re-

The prognostic significance of proliferating cell nuclear antigen,
epidermal growth factor receptor, and MDR gene expression in

8. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascu-
lar endothelial growth factor, CD68, and epidermal growth factor
receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in progo-

9. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerat-
ed tumor clonogen repopulation during radiotherapy. Acta Oncol

lation in experimental squamous cell carcinoma. In: Kogelnik HD,
Lukas P, Sedlmaier F, Progress in radiation-oncology. Vol. 7. Bolo-
gna, Monduzzi 2002; 417-22.

11. Begg AC. Prediction of repopulation rates and radiosensitivity in

12. Withers HR. The 4 R’s of radiotherapy. In: Lett JT, Alder H. Advanc-
241-71.

13. Withers HR. The 4 R’s of radiotherapy. In: Lett JT, Alder H. Advanc-
241-71.


15. Mlak R, Powrózek T, Nicoś M, Kowalski DM, Wło-

czuk P, Mlak R, Powrózek T, Nicoś M, Kowalski DM, Wło-

czuk P, Mlak R, Powrózek T, Nicoś M, Kowalski DM, Wło-

EGF receptor ligand system for tumour progression and survival
in gastrointestinal carcinomas: evidence for new therapeutic op-
42. This study was supported by the Scientific Board of Regional Hospital Liberec, Research Project UK – LF HK: PRVOUK P37/06.

Address for correspondence
Igor Richter MD
Department of Oncology, Regional Hospital Liberec
Husova 10
460 63, Liberec, Czech Republic
e-mail: igor.richter@seznam.cz
Submitted: 29.04.2014
Accepted: 16.07.2014